Bacteria, genetics and irritable bowel syndrome

References

• Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis.15, 237–241 (2006).
   PubMedGoogle Scholar
• Bommelaer G, Poynard T, Le Pen C et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol. Clin. Biol.28, 554–561 (2004).
   PubMed Web of Science ®Google Scholar
• Boyce PM, Talley NJ, Burke C, Koloski NA. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. Intern. Med. J.36, 28–36 (2006).
   PubMed Web of Science ®Google Scholar
• Jones R, Lydeard S. Irritable bowel syndrome in the general population. Br. Med. J.304, 87–90 (1992).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ 3rd. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology101, 927–934 (1991).
   PubMed Web of Science ®Google Scholar
• Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br. J. Gen. Pract.54, 495–502 (2004).
   PubMed Web of Science ®Google Scholar
• Wilson A, Longstreth GF, Knight K et al. Quality of life in managed care patients with irritable bowel syndrome. Manag. Care Interface17, 24–28, 34 (2004).
   PubMedGoogle Scholar
• Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci.38, 1569–1580 (1993).
   PubMed Web of Science ®Google Scholar
• Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther.17, 643–650 (2003).
   PubMed Web of Science ®Google Scholar
• Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics24, 21–37 (2006).
   PubMed Web of Science ®Google Scholar
• Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J. Gastroenterol.14, 2639–2649 (2008).
   PubMed Web of Science ®Google Scholar
• Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology124, 1662–1671 (2003).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Hawkey CJ, Mayer EA et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment. Pharmacol. Ther.15, 959–964 (2001).
   PubMed Web of Science ®Google Scholar
• Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut53, 1096–1101 (2004).
   PubMed Web of Science ®Google Scholar
• Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut44, 400–406 (1999).
   PubMed Web of Science ®Google Scholar
• Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br. Med. J.314, 779–782 (1997).
   PubMed Web of Science ®Google Scholar
• Mearin F, Perez-Oliveras M, Perello A et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology129, 98–104 (2005).
   PubMed Web of Science ®Google Scholar
• Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut51, 410–413 (2002).
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology131, 445–450; quiz 660 (2006).
   PubMed Web of Science ®Google Scholar
• Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut52, 523–526 (2003).
   PubMed Web of Science ®Google Scholar
• Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet347, 150–153 (1996).
   PubMed Web of Science ®Google Scholar
• Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am. J. Gastroenterol.98, 1578–1583 (2003).
   PubMed Web of Science ®Google Scholar
• Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut47, 804–811 (2000).
   PubMed Web of Science ®Google Scholar
• Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology132, 913–920 (2007).
   PubMed Web of Science ®Google Scholar
• Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol.103, 2570–2576 (2008).
   PubMed Web of Science ®Google Scholar
• O’Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology128, 541–551 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment. Pharmacol. Ther.20, 1317–1322 (2004).
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut27, 37–40 (1986).
   PubMed Web of Science ®Google Scholar
• Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ 3rd. Familial association in adults with functional gastrointestinal disorders. Mayo Clin. Proc.75, 907–912 (2000).
   PubMed Web of Science ®Google Scholar
• Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology121, 799–804 (2001).
   PubMed Web of Science ®Google Scholar
• Lembo A, Zaman M, Jones M, Talley NJ. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment. Pharmacol. Ther.25, 1343–1350 (2007).
   PubMed Web of Science ®Google Scholar
• Dinan TG, Cryan J, Shanahan F, Keeling PWN, Quigley EMM. Irritable bowel syndrome: an epigenetic perspective. Nat. Rev. Gastroenterol. (In press).
   Google Scholar
• Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del Tacca M. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol. Med.14, 295–304 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri M, Carlson PJ et al. Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut53, 829–837 (2004).
   PubMed Web of Science ®Google Scholar
• Pata C, Erdal ME, Derici E, Yazar A, Kanik A, Ulu O. Serotonin transporter gene polymorphism in irritable bowel syndrome. Am. J. Gastroenterol.97, 1780–1784 (2002).
   PubMed Web of Science ®Google Scholar
• Van Kerkhoven LA, Laheij RJ, Jansen JB. Meta-analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndrome. Aliment. Pharmacol. Ther.26, 979–986 (2007).
   PubMed Web of Science ®Google Scholar
• Camilleri M. Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. Dig. Dis. Sci.54, 2318–2324 (2009).
   PubMed Web of Science ®Google Scholar
• Quigley EMM. Functional gastrointestinal disorders; has the genomic era arrived? Gastroenterology126, 1193–1195 (2004).
   PubMed Web of Science ®Google Scholar
• Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology138, 1276–1285 (2010).
   PubMed Web of Science ®Google Scholar
• Richards A. The Walkerton Health Study. Can. Nurse101, 16–21 (2005).
   PubMedGoogle Scholar
• Wu S, Rhee KJ, Zhang M, Franco A, Sears CL. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage. J. Cell Sci.120, 1944–1952 (2007).
   PubMed Web of Science ®Google Scholar
• Frank CF, Hostetter MK. Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by Candida albicans. Transl. Res.149, 211–222 (2007).
   PubMed Web of Science ®Google Scholar
• Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am. J. Gastroenterol.101, 1295–1298 (2006).
   PubMed Web of Science ®Google Scholar
• Houlston RS, Webb E, Broderick P et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat. Genet.40, 1426–1435 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett JC, Lee JC, Lees CW et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat. Genet.41, 1330–1334 (2009).
   PubMed Web of Science ®Google Scholar
• Muise AM, Walters TD, Glowacka WK et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease. Gut58, 1121–1127 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke G, Quigley EMM, Cryan JF, Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol. Med.15, 478–489 (2009).
   PubMed Web of Science ®Google Scholar
• Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology133, 799–807 (2007).
   PubMed Web of Science ®Google Scholar
• Villani AC, Saito AY, Lemire M et al. Validation of genetic risk factors for post-infectious irritable bowel syndrome (IBS) in patients with sporadic IBS. Gastroenterology136(5 Suppl. 1), A-68 (2009).
   Google Scholar
• Wang BM, Wang YM, Zhang WM et al. [Serotonin transporter gene polymorphism in irritable bowel syndrome]. Zhonghua Nei Ke Za Zhi43, 439–441 (2004).
   PubMedGoogle Scholar
• Park JM, Choi MG, Park JA et al. Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol. Motil.18, 995–1000 (2006).
   PubMed Web of Science ®Google Scholar
• Odunsi ST, Camilleri M, Bharucha AE et al. Reproducibility and performance characteristics of colonic compliance, tone, and sensory tests in healthy humans. Dig. Dis. Sci.55, 709–715 (2010).
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, McKinzie S et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am. J. Physiol. Gastrointest. Liver Physiol.294, G13–G19 (2008).
   PubMed Web of Science ®Google Scholar
• Melum E, Franke A, Karlsen TH. Genome-wide association studies – a summary for the clinical gastroenterologist. World J. Gastroenterol.15, 5377–5396 (2009).
   PubMed Web of Science ®Google Scholar
• Dinan TG, Clarke G, Quigley EM et al. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am. J. Gastroenterol.103, 2570–2576 (2008).
   PubMed Web of Science ®Google Scholar
• Scully P, McKernan DP, Keohane J et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am. J. Gastroenterol. DOI: 10.1038/ajg.2010.159 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• O’Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum. Psychopharmacol.19, 397–403 (2004).
   PubMed Web of Science ®Google Scholar
• Keita AV, Soderholm JD, Ericson AC. Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells. Neurogastroenterol. Motil. DOI: 10.1111/j.1365-2982.2010.01471.x (2010) (Epub ahead of print).
   Google Scholar
• Keita AV, Söderholm JD. The intestinal barrier and its regulation by neuroimmune factors. Neurogastroenterol. Motil. DOI: 10.1111/j.1365-2982.2010.01498.x (2010) (Epub ahead of print).
   Google Scholar
• Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am. J. Physiol. Gastrointest. Liver Physiol.298(6), G807–G819 (2010).
   PubMed Web of Science ®Google Scholar